In EGFR-mutant NSCLC patients, osimertinib has reported higher intracranial activity compared with chemotherapy (51) and first-generation EGFR TKIs (17), and longer delay of onset of BM (51). This evidence concerns the gene EGFR and non-small cell lung carcinoma.